EMD-60799

Single-particle
3.19 Å
EMD-60799 Deposition: 13/07/2024
Map released: 11/12/2024
Last modified: 25/12/2024
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links

EMD-60799

Cryo-EM structure of Nipah virus L-P polymerase complex

EMD-60799

Single-particle
3.19 Å
EMD-60799 Deposition: 13/07/2024
Map released: 11/12/2024
Last modified: 25/12/2024
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Sample Organism: Nipah virus
Sample: Cryo-EM structure of Nipah virus L-P polymerase complex
Fitted models: 9ir3 (Avg. Q-score: )

Deposition Authors: Shi Y , Peng Q
Cryo-EM structure of Nipah virus L-P polymerase complex.
Peng Q, Dong Y, Jia M, Liu Q, Bi Y , Qi J , Shi Y
(2024) Nat Commun , 15 , 10524 - 10524
PUBMED: 39627254
DOI: doi:10.1038/s41467-024-54994-5
ISSN: 2041-1723
Abstract:
Nipah virus (NiV) is a non-segmented, negative-strand (NNS) RNA virus, belonging to Paramyxoviridae. The RNA polymerase complex, composed of large (L) protein and tetrameric phosphoprotein (P), is responsible for genome transcription and replication by catalyzing NTP polymerization, mRNA capping and cap methylation. Here, we determine the cryo-electron microscopy (cryo-EM) structure of fully bioactive NiV L-P polymerase complex at a resolution of 3.19 Å. The L-P complex displays a conserved architecture like other NNS RNA virus polymerases and L interacts with the oligomerization domain and the extreme C-terminus region of P tetramer. Moreover, we elucidate that NiV is naturally resistant to the allosteric L-targeting inhibitor GHP-88309 due to the conformational change in the drug binding site. We also find that the non-nucleotide drug suramin can inhibit the NiV L-P polymerase activity at both the enzymatic and cellular levels. Our findings have greatly enhanced the molecular understanding of NiV genome replication and transcription and provided the rationale for broad-spectrum polymerase-targeted drug design.